Advertisement
The IPSOS phase III trial aimed to assess if the efficacy and tolerability of atezolizumab monotherapy in Asian NSCLC patients with no PDC eligibility mirrored the wider IPSOS trial results. The primary endpoint was OS. The study exhibited consistent safety and efficacy with ITT results, validating its performance in PDC-ineligible patients. S.M. Lee […]...
Advertisement
Advertisement
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Advertisement
Background Cancer neoantigens arise from protein-altering somatic mutations in tumor and rank among the most promising next-generation immuno-oncology agents when used in combination with immune checkpoint inhibitors. We previously developed a computational framework, REAL-neo, for identification, …
Background Only a subset of patients with gastric cancer experience long-term benefits from immune checkpoint inhibitors (ICIs). Currently, there is a deficiency in precise predictive biomarkers for ICI efficacy. The aim of this study was to …
Background Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies. If CAR-T cell therapy for non-hematological …
Background Cancer-intrinsic type I interferon (IFN-I) production triggered by radiotherapy (RT) is mainly dependent on cytosolic double-stranded DNA (dsDNA)-mediated cGAS/STING signaling and increases cancer immunogenicity and enhances the antitumor immune response to increase therapeutic efficacy. However, …
